Correlación del cociente PSA complex/PSA total con el cociente PSA libre/PSA total, sensibilidad y especificidad de ambos marcadores para el diagnóstico del cáncer de prostata / Correlation between the Complex PSA/total PSA Ratio and the Free PSA/total PSA Ratio, Sensitivity and Specificity of Both Markers for the Diagnosis of Prostate Cancer

Objetivo: Comparamos el comportamiento del cociente PSA complex/PSA total porcentual (PSAc%) frente al cociente PSA libre/PSA total (PSAl%) y analizamos ambos marcadores en su utilidad para el diagnóstico del cáncer de próstata. Material y métodos: Se midieron los niveles de PSA total (PSAt), PSA libre (PSAl), PSA complex (PSAc), PSAl% y PSAc% en 158 pacientes. Noventa y ocho (62%) fueron biopsiados si presentaban PSAt ≥3 ng/dl y PSAl% < 20, PSAt > 10, tacto rectal sospechoso o nódulo ecográfico sospechoso. Se realizó un análisis de regresión lineal y de regresión Passing-Bablock. Se calcularon las curvas ROC para estudiar la sensibilidad y especificidad del PSAl% y PSAc% y se compararon entre ellas. Se analizaron los diagnósticos de cáncer de próstata por el PSAl% y el PSAc% aplicando el test χ2. Resultados: El coeficiente de correlación (r) fue bueno, 0,7447 (p < 0,0001) y el índice de determinación (r2) fue de 0,5. El resultado del análisis Passing-Bablock fue una pendiente de 1.658 (1.452 a 1.897) e intersección de 2.044 (−0,936 a 5.393). El punto de corte óptimo de PSAl%, ≤ 14.7854, mostró una sensibilidad del 89,29% (IC 95%; 0,642-0,823) y una especificidad del 54,29% (IC 95%; 0,642-0,823) y el punto de corte óptimo de PSAc%, > 89.7796, una sensibilidad del 71,43% (IC 95%; 0,616-0,802) y una especificidad del 71,43% (IC 95%; 0,616-0,802). No hubo diferencias significativas al comparar las áreas bajo la curva de ambos marcadores (p = 0,59). El VPP del PSAl% fue menor respecto al PSAc% (45,7% vs 71%). Conclusión: Existe una buena correlación entre el PSAl% y PSAc%. El PSAc% ha demostrado una mayor especificidad y eficacia que el PSAl% en el diagnóstico del cáncer de próstata (AU)

Objective: To compare the behaviour of the PSAcomplex/PSAtotal percentage (PSAc%) against the PSA free/PSA total (PSAl%) and analyse both markers for their usefulness in diagnosing prostate cancer. Material and methods: We measured total PSA (PSAt), free PSA (PSAl), complex PSA (PSAc), PSAl% and PSAc% levels in 158 patients. Of these, 98 (62%) were biopsied for presenting PSAt ≥3 ng/dl and PSAl% < 20, PSAt > 10, suspicious rectal examination or suspicious ultrasound node. We performed linear regression and Passing-Bablok regression analyses. The ROC curves were calculated to study the sensitivity and specificity of PSAl% and PSAc% and were compared to each other. The prostate cancer diagnoses were analysed by PSAl% and PSAc% by applying the χ2 test. Results: The correlation coefficient (r) was good (0.7447, P <0 .0001), and the index of determination (r2) was 0,5. The result of the Passing-Bablok analysis was a slope of 1.658 (1.452 to 1.897) and an intersection of 2.044 (−0,936 to 5.393). The optimal cutoff for PSAl% (≤ 14.7854) showed a sensitivity of 89.29% [95% CI, 0,642-0,823] and a specificity of 54.29% (95% CI, 0,642-0,823). The optimal cutoff for PSAc% (>89.7796) had a sensitivity of 71.43% (95% CI, 0,616-0,802) and a specificity of 71.43% (95% CI, 0,616-0,802). There were no significant differences when comparing the areas under the curve of both markers (P = 0.59). The PPV of PSAl% was less than that of PSAc% (45.7% vs. 71%). Conclusion: There was a good correlation between PSAl% and PSAc%. PSAc% has demonstrated greater specificity and efficacy than PSAl% in the diagnosis of prostate cancer (AU)

Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer.

OBJECTIVE: To compare the behaviour of the PSAcomplex/PSAtotal percentage (PSAc%) against the PSA free/PSA total (PSAl%) and analyse both markers for their usefulness in diagnosing prostate cancer. MATERIAL AND METHODS: We measured total PSA (PSAt), free PSA (PSAl), complex PSA (PSAc), PSAl% and PSAc% levels in 158 patients. Of these, 98 (62%) were biopsied for presenting PSAt≥3 ng/dl and PSAl%<20, PSAt>10, suspicious rectal examination or suspicious ultrasound node. We performed linear regression and Passing-Bablok regression analyses. The ROC curves were calculated to study the sensitivity and specificity of PSAl% and PSAc% and were compared to each other. The prostate cancer diagnoses were analysed by PSAl% and PSAc% by applying the χ(2) test. RESULTS: The correlation coefficient (r) was good (0.7447, P<.0001), and the index of determination (r(2)) was 0,5. The result of the Passing-Bablok analysis was a slope of 1.658 (1.452 to 1.897) and an intersection of 2.044 (-0,936 to 5.393). The optimal cutoff for PSAl% (≤14.7854) showed a sensitivity of 89.29% [95% CI, 0,642-0,823] and a specificity of 54.29% (95% CI, 0,642-0,823). The optimal cutoff for PSAc% (>89.7796) had a sensitivity of 71.43% (95% CI, 0,616-0,802) and a specificity of 71.43% (95% CI, 0,616-0,802). There were no significant differences when comparing the areas under the curve of both markers (P=.59). The PPV of PSAl% was less than that of PSAc% (45.7% vs. 71%). CONCLUSION: There was a good correlation between PSAl% and PSAc%. PSAc% has demonstrated greater specificity and efficacy than PSAl% in the diagnosis of prostate cancer.

[Prognostic value of E-cadherina, beta catenin, Ki-67 antigen and p53 protein in the superficial bladder tumors]. / Cadherina E, catenina beta, antígeno Ki-67 y proteína p53 en el pronóstico de la recidiva tumoral en los tumores superficiales de vejiga T1.

INTRODUCTION: The natural history of the superficial carcinoma of bladder is characterized by his high rate of recurrence and by the aptitude to progress to higher stages. We are going to investigate the capacity of prediction for tumor recurrence of protein p53, antigen Ki-67, E Cadherin and Beta Catenin MATERIAL AND METHOD: 88 T1 tumors with a median of free time of disease of 36 months. 58% of the serie has received prophylactic treatment with BCG 81 mg. weekly for six weeks. Cut-oof level for For P53 and Ki-67 is 10 % of stained cells. For E Cadherin and Beta Catenin we have established two groups: one with the values 0-4 (negative), and other one with the values 5-8 (positive). RESULTS: Recurrence rate 31%, stage progression 3%. Ki-67 expression is correlated with grade (p .002) and lymphatic permeation (p .028). Multiplicity is correlated with lack( of Cadherin and Catenin's expression. Only Ki-67 expression (p .049) and lack of Beta Catenin expression (p .039) reach statistical significance. In multivariant study only lack of Beta Catenin's expression shows independent recurrence value (p .049; O.R: 2,4-6,9) CONCLUSIONS: The most useful prognmostic markers are Ki-67 and Catenina Beta Only Beta Catenin Beta shows independent value for tumour recurrence. Tumors wich lack expression for Catenin B or Cadherin E have lower recurrence free time.

Cadherina E, Catenina Beta, Antígeno Ki-67 y proteína p53 en el pronóstico de la recidiva tumoral en los tumores superficiales de vejiga T1 / Prognostic value of E-Cadherina, Beta Catenin, K1, Ki-67 antigen and p53 protein in the superficial bladder tumors

Introducción: La historia natural del carcinoma superficial de vejiga (CSV) se caracteriza por su alta tasa de recidivas y por la capacidad de progresar a estadios infiltrantes. Vamos a investigar la capacidad de predicción de recidiva tumoral de la proteína p53, el antígeno Ki-67 y las moléculas de adhesión celular Cadherina E y Catenina Beta Material y método: 88 tumores T1 con una mediana de tiempo libre de enfermedad de 36 meses. Han recibido tratamiento profiláctico con BCG 81 mg. semanal durante seis semanas el 58% de la serie. Para p53 y Ki-67 se estableció el nivel de 10% de células teñidas para considerar positivo el tumor. Para Cadherina E y Catenina se han establecido dos grupos: uno con los valores 0-4 (negativo), y otro con los valores 5-8 (positivo). Resultados: Han recidivado el 31% de los tumores y progresado a estadio infiltrante el 3% La expresión de Ki-67 se correlaciona con grado (p ,002) y permeación linfática (p ,028). La multiplicidad tumoral con la falta de expresión de Cadherina E y Catenina Beta. Sólo la expresión de Ki-67 (p .049) y la de Catenina Beta (p .039) alcanzan significación estadística. En el estudio multivariante sólo la falta de expresión de Catenina Beta muestra tener valor pronóstico independiente para recidiva (p .049; O.R : 2,4-6,9) Conclusiones: Los marcadores más útiles son Ki-67 y Catenina Beta. Sólo la Catenina Beta muestra un valor independiente para recidiva tumoral. Los tumores que no expresan Catenina Beta o Cadherina E tienen un menor tiempo libre de recidiva

Introduction: The natural history of the superficial carcinoma of bladder is characterized by his high rate of recurrence and by the aptitude to progress to higher stages. We are going to investigate the capacity of prediction for tumor recurrence of protein p53, antigen Ki-67, E Cadherin and Beta Catenin Material and method: 88 T1 tumors with a median of free time of disease of 36 months. 58% of the serie has received prophylactic treatment with BCG 81 mg. weekly for six weeks. Cut-oof level for For P53 and Ki-67 is 10 % of stained cells. For E Cadherin and Beta Catenin we have established two groups: one with the values 0-4 (negative), and other one with the values 5-8 (positive). Results: Recurrence rate 31 %, stage progression 3 %. Ki-67 expression is correlated with grade (p .002) and lymphatic permeation (p .028). Multiplicity is correlated with lack( of Cadherin and Catenin´s expression. Only Ki-67 expression (p .049) and lack of Beta Catenin expression (p .039) reach statistical significance. In multivariant study only lack of Beta Catenin’s expression shows independent recurrence value (p .049; O.R: 2,4-6,9) Conclusions: The most useful prognmostic markers are Ki-67 and Catenina Beta Only Beta Catenin Beta shows independent value for tumour recurrence. Tumors wich lack expression for Catenin B or Cadherin E have lower recurrence free time